RioDerm-003 is under clinical development by Rion and currently in Phase I for Radiodermatitis. According to GlobalData, Phase I drugs for Radiodermatitis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the RioDerm-003 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RioDerm-003 overview

RioDerm-003 is under development for the treatment of radiation dermatitis. The therapeutic candidate comprises of exosomes containing platelet exosome product (PEP) with a carbomer carrier. It is formulated in the form of powder and is being developed based on next-gen platelet-derived exosome technology.

Rion overview

Rion is a clinical-stage biotechnology company. It focuses on developing exosome therapies. The company’s product pipeline includes therapies for the treatment of acute myocardial infarction, female stress urinary incontinence, musculoskeletal and wound healing. It develops Purified Exosome Product (PEP), an innovative biologic platform that optimizes the therapeutic power of exosomes for regenerative medicine. Rion is headquartered in Rochester, Minnesota, the US.

For a complete picture of RioDerm-003’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.